SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
98,000
-600 (-0.61%)
At close: Sep 1, 2025

SK Biopharmaceuticals Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Net Income
255,991240,738-32,883-139,43164,846-247,414
Upgrade
Depreciation & Amortization
17,72417,42815,31712,98411,64210,859
Upgrade
Loss (Gain) From Sale of Assets
8.26-171.0218.7211.283.020.29
Upgrade
Asset Writedown & Restructuring Costs
--6,808172.96--
Upgrade
Loss (Gain) From Sale of Investments
947.431,396-12,2432,858-2,208-1,987
Upgrade
Loss (Gain) on Equity Investments
38,21731,25311,53514,92734,544-
Upgrade
Stock-Based Compensation
5,1107,5113,23360.66416.71-
Upgrade
Other Operating Activities
-146,350-170,591-10,34514,161-132,4027,091
Upgrade
Change in Accounts Receivable
-53,729-37,064-52,456-13,169-41,610-9,050
Upgrade
Change in Inventory
17,630-8,593-13,708-38,693-29,459-16,630
Upgrade
Change in Accounts Payable
-14,902940.7-20,7116,965607.698,961
Upgrade
Change in Other Net Operating Assets
-17,41812,05311,232-20,767748.3837,443
Upgrade
Operating Cash Flow
103,22994,900-94,201-159,920-92,872-210,726
Upgrade
Capital Expenditures
-2,233-1,395-2,385-4,911-4,316-11,023
Upgrade
Sale of Property, Plant & Equipment
----11.24-
Upgrade
Cash Acquisitions
--31,043---
Upgrade
Sale (Purchase) of Intangibles
-12,178-10,726-864.17-1,050-1,676-3,314
Upgrade
Investment in Securities
-2,1833,506198,587-89,691265,618-303,722
Upgrade
Other Investing Activities
-2,932-2,340-1,104-10.78-639.56-714.24
Upgrade
Investing Cash Flow
-19,447-10,941225,273-95,714258,971-318,730
Upgrade
Short-Term Debt Issued
-100,000---150,000
Upgrade
Long-Term Debt Issued
---141,751--
Upgrade
Total Debt Issued
-100,000-141,751-150,000
Upgrade
Short-Term Debt Repaid
--50,000----250,000
Upgrade
Long-Term Debt Repaid
--54,498-5,575-5,477-4,827-4,562
Upgrade
Total Debt Repaid
-155,385-104,498-5,575-5,477-4,827-254,562
Upgrade
Net Debt Issued (Repaid)
-155,385-4,498-5,575136,274-4,827-104,562
Upgrade
Issuance of Common Stock
-----645,465
Upgrade
Other Financing Activities
0.380.3812,198-1,360180.69-
Upgrade
Financing Cash Flow
-155,385-4,4986,623134,914-4,646540,902
Upgrade
Foreign Exchange Rate Adjustments
7,7253,646-2,054-1,1435,135-3,254
Upgrade
Miscellaneous Cash Flow Adjustments
----0-
Upgrade
Net Cash Flow
-63,87783,107135,640-121,863166,5898,192
Upgrade
Free Cash Flow
100,99793,505-96,586-164,831-97,188-221,749
Upgrade
Free Cash Flow Margin
16.28%17.08%-27.22%-66.96%-23.21%-852.91%
Upgrade
Free Cash Flow Per Share
1289.651193.98-1233.34-2104.77-1241.01-3089.90
Upgrade
Cash Interest Paid
8,8459,4998,1423,488844.194,441
Upgrade
Cash Income Tax Paid
21,25012,1548,1264,6816,1606,389
Upgrade
Levered Free Cash Flow
64,38633,476-54,562-108,21051,274-163,014
Upgrade
Unlevered Free Cash Flow
70,64540,152-49,387-105,88851,865-160,225
Upgrade
Change in Working Capital
-68,419-32,663-75,643-65,664-69,71320,725
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.